{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:57:57Z","timestamp":1785560277556,"version":"3.56.0"},"reference-count":37,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2026,7,31]]},"DOI":"10.1536\/ihj.25-558","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:10:53Z","timestamp":1783980653000},"page":"298-305","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of 15 mg Edoxaban on Long-Term Outcome after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and High Bleeding Risk"],"prefix":"10.1536","volume":"67","author":[{"given":"Takao","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifusa","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Tachikawa General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoma","family":"Fukuoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tanimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Tanimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Sugimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Kiyooka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IUHW Atami Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","unstructured":"1. Camm AJ, Lip GYH, De Caterina R, <i>et al<\/i>. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, <i>et al<\/i>. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.","DOI":"10.1093\/eurheartj\/ehq278"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Go AS, Hylek EM, Phillips KA, <i>et al<\/i>. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.","DOI":"10.1001\/jama.285.18.2370"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sato T, Aizawa Y, Fuse K, <i>et al<\/i>. The comparison of inappropriate-low-doses use among 4 direct oral anticoagulants in patients with atrial fibrillation: from the database of a single-center registry. J Stroke Cerebrovasc Dis 2018; 27: 3280-8.","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.07.028"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Toyoda K, Yasaka M, Iwade K, <i>et al<\/i>. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke 2008; 39: 1740-5.","DOI":"10.1161\/STROKEAHA.107.504993"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Lamberts M, Gislason GH, Lip GYH, <i>et al<\/i>. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014; 129: 1577-85.","DOI":"10.1161\/CIRCULATIONAHA.113.004834"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Dewilde WJM, Oirbans T, Verheugt FWA, <i>et al<\/i>. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-15.","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kang J, Park KW, Palmerini T, <i>et al<\/i>. Racial differences in ischaemia\/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost 2019; 119: 149-62.","DOI":"10.1055\/s-0038-1676545"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Okumura K, Akao M, Yoshida T, <i>et al<\/i>. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020; 383: 1735-45.","DOI":"10.1056\/NEJMoa2012883"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Giugliano RP, Ruff CT, Braunwald E, <i>et al<\/i>. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104.","DOI":"10.1056\/NEJMoa1310907"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Iwasaki YK, Noda T, Akao M, <i>et al<\/i>. JCS\/JHRS 2024 Guideline Focused Update on Management of Cardiac Arrhythmias. Circ J 2025; 89: 1012-73.","DOI":"10.1253\/circj.CJ-24-0073"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Natsuaki M, Morimoto T, Yamaji K, <i>et al<\/i>. Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-kyoto thrombotic and bleeding risk scores. J Am Heart Assoc 2018; 7: e008708.","DOI":"10.1161\/JAHA.118.008708"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sato T, Matsumura M, Yamamoto K, <i>et al<\/i>. A Revised Optical Coherence Tomography-Derived Calcium Score to Predict Stent Underexpansion in Severely Calcified Lesions. JACC Cardiovasc Interv 2025; 18: 622-33.","DOI":"10.1016\/j.jcin.2024.12.001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hindricks G, Potpara T, Dagres N, <i>et al<\/i>. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498.","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakamura M, Yaku H, Ako J, <i>et al<\/i>. JCS\/JSCVS 2018 guideline on revascularization of stable coronary artery disease. Circ J 2022; 86: 477-588.","DOI":"10.1253\/circj.CJ-20-1282"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Angiolillo DJ, Goodman SG, Bhatt DL, <i>et al<\/i>. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a north american perspective-2018 Update. Circulation 2018; 138: 527-36.","DOI":"10.1161\/CIRCULATIONAHA.118.034722"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Thygesen K, Alpert JS, Jaffe AS, <i>et al<\/i>. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019; 40: 237-69.","DOI":"10.1093\/eurheartj\/ehy856"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Garcia-Garcia HM, McFadden EP, Farb A, <i>et al<\/i>. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation 2018; 137: 2635-50.","DOI":"10.1161\/CIRCULATIONAHA.117.029289"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Schulman S, Kearon C; Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. De Caterina R, Agewall S, Andreotti F, <i>et al<\/i>. Great debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. Eur Heart J 2022; 43: 3512-27.","DOI":"10.1093\/eurheartj\/ehac294"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lamberts M, Gislason GH, Olesen JB, <i>et al<\/i>. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013; 62: 981-9.","DOI":"10.1016\/j.jacc.2013.05.029"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Gibson CM, Mehran R, Bode C, <i>et al<\/i>. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 2015; 169: 472-8.","DOI":"10.1016\/j.ahj.2014.12.006"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Lopes RD, Vora AN, Liaw D, <i>et al<\/i>. An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and\/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. Am Heart J 2018; 200: 17-23.","DOI":"10.1016\/j.ahj.2018.03.001"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Vranckx P, Valgimigli M, Eckardt L, <i>et al<\/i>. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019; 394: 1335-43.","DOI":"10.1016\/S0140-6736(19)31872-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Cannon CP, Bhatt DL, Oldgren J, <i>et al<\/i>. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377: 1513-24.","DOI":"10.1056\/NEJMoa1708454"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Gargiulo G, Goette A, Tijssen J, <i>et al<\/i>. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J 2019; 40: 3757-67.","DOI":"10.1093\/eurheartj\/ehz732"},{"key":"27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/europace\/euz259","volume":"22","year":"2020","unstructured":"27. Potpara TS, Mujovic N, Proietti M, <i>et al<\/i>. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace 2020; 22: 33-46.","journal-title":"Europace","ISSN":"https:\/\/id.crossref.org\/issn\/1099-5129","issn-type":"print"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Neumann FJ, Sousa-Uva M, Ahlsson A, <i>et al<\/i>. 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87-165.","DOI":"10.1093\/eurheartj\/ehy855"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Yasuda S, Kaikita K, Akao M, <i>et al<\/i>. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019; 381: 1103-13.","DOI":"10.1056\/NEJMoa1904143"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Matsumura-Nakano Y, Shizuta S, Komasa A, <i>et al<\/i>. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation 2019; 139: 604-16.","DOI":"10.1161\/CIRCULATIONAHA.118.036768"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Akao M, Chun YH, Esato M, <i>et al<\/i>. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J 2014; 78: 2166-72.","DOI":"10.1253\/circj.CJ-14-0344"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Ruff CT, Giugliano RP, Braunwald E, <i>et al<\/i>. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-62.","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kato ET, Goto S, Giugliano RP. Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev 2019; 49: 115-24.","DOI":"10.1016\/j.arr.2018.10.006"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kaikita K, Yasuda S, Akao M, <i>et al<\/i>. Bleeding and subsequent cardiovascular events and death in atrial fibrillation with stable coronary artery disease: insights from the AFIRE trial. Circ Cardiovasc Interv 2021; 14: e010476.","DOI":"10.1161\/CIRCINTERVENTIONS.120.010476"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Cho MS, Kang DY, Ahn JM, <i>et al<\/i>. Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease. N Engl J Med 2024; 391: 2075-86.","DOI":"10.1056\/NEJMe2410903"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Fukamachi D, Okumura Y, Matsumoto N, <i>et al<\/i>. Edoxaban monotherapy in nonvalvular atrial fibrillation patients with coronary artery disease. J Interv Cardiol 2022; 2022: 5905022.","DOI":"10.1155\/2022\/5905022"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Watanabe H, Domei T, Morimoto T, <i>et al<\/i>. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 2019; 321: 2414-27.","DOI":"10.1001\/jama.2019.8145"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/4\/67_25-558\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:14:04Z","timestamp":1785557644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/4\/67_25-558\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.25-558","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"25-558"}}